EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.68
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$37.58

06 Aug
2025

0.110

OPEN

$37.35

0.29%

HIGH

$37.83

61,603

LOW

$37.21

TARGET
$36.317 -3.4% downside
Franking for last dividend paid out: 96%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . HLS . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 141.3 137.2 xxx
DPS (cps) xxx N/A 107.3 xxx
EPS Growth xxx 6.3% - 2.9% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 27.7 xxx
Dividend Yield xxx N/A 2.8% xxx
Div Pay Ratio(%) xxx N/A 78.2% xxx

Dividend yield today if purchased 3 years ago: 1.60%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.48

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/08 - ex-div 49.71c (franking 49%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx141.3
DPS All xxxxxxxxxxxxxxx114.5
Sales/Revenue xxxxxxxxxxxxxxx13,189.1 M
Book Value Per Share xxxxxxxxxxxxxxx1,268.4
Net Operating Cash Flow xxxxxxxxxxxxxxx348.2 M
Net Profit Margin xxxxxxxxxxxxxxx2.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx11.12 %
Return on Invested Capital xxxxxxxxxxxxxxx7.88 %
Return on Assets xxxxxxxxxxxxxxx4.12 %
Return on Equity xxxxxxxxxxxxxxx11.12 %
Return on Total Capital xxxxxxxxxxxxxxx12.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx96.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx823 M
Long Term Debt xxxxxxxxxxxxxxx820 M
Total Debt xxxxxxxxxxxxxxx1,643 M
Goodwill - Gross xxxxxxxxxxxxxxx2,068 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx217 M
Price To Book Value xxxxxxxxxxxxxxx2.32

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx118.8 M
Capex % of Sales xxxxxxxxxxxxxxx0.90 %
Cost of Goods Sold xxxxxxxxxxxxxxx12,232 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx474 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx89 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

11/04/2025

5

Sell

$32.00

-14.85%

Ebos Group acquired New Zealand company SVS for $105m upfront plus potential earn-outs, and the transaction closed on March 31.

The company is raising $200m via fully underwritten placement and also plans a retail offer for up to $50m. Additionally, it acquired the balance 10% of Transmedic for $35m.

Citi estimates the net result of all these transactions will be excess cash of $95m, which it reckons will provide capacity for more M&A. The effect on FY26 EPS is a 1-2% accretion, according to the broker.

Sell retained. Target unchanged at $32.

FORECAST
Citi forecasts a full year FY25 dividend of 103.90 cents and EPS of 137.10 cents.
Citi forecasts a full year FY26 dividend of 107.30 cents and EPS of 152.30 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

24/07/2025

2

Overweight

-

-

Jarden reiterates its Overweight rating on Ebos Group, noting the strong structural growth in PBS expenditure as a key underpinning of the company's forward earnings.

The broker highlights an around 9% compound annual growth rate (CAGR) in PBS spend over the past three years.

This growth rate is supported by drug innovation and a favourable regulatory backdrop under the 8th Community Pharmacy Agreement and First Pharmaceutical Wholesaler Agreement, explain the analysts.

The group is expected to benefit from consistent high single-digit growth in S-85 (Community Pharmacy) and circa 7% growth in S-100 (Hospital), with additional upside from GLP-1 penetration if PBS expands coverage.

The broker flags potential EPS upgrades by the market pending policy clarity and lifts its FY27 and FY28 forecasts by 2% and 3% respectively. The target price is raised to NZ$43.20 from NZ$41.60.

FORECAST
Jarden forecasts a full year FY25 dividend of 108.00 cents and EPS of 143.50 cents.
Jarden forecasts a full year FY26 dividend of 113.00 cents and EPS of 161.00 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Australian Broker Call *Extra* Edition – Jul 24, 2025

Jul 24 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Jul 21, 2025

Jul 21 2025 - Daily Market Reports
3
In Brief: Sigma, Domino’s, Clarity & SiteMinder

Jun 20 2025 - Weekly Reports
4
Next Week At A Glance – 2-6 June 2025

May 30 2025 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Apr 15, 2025

Apr 16 2025 - Daily Market Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps